

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2014

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Massachusetts	000-21615	04-2652826
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

14 Norfolk Avenue
South Easton, Massachusetts 02375

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

The Company presented at the Rodman and Renshaw Global Investment Conference on September 10, 2014. The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 8.01 as if fully set forth herein.

The information contained in this Current Report, including Exhibit 99.1 are being furnished and not filed pursuant to this Item 8.01 of Form 8-K. Such information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits

Exhibit

No. Description

[99.1](#) Company information – “Power Point Presentation” dated September 10, 2014 (filed herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRESSURE BIOSCIENCES, INC.

Date: September 16, 2014

By: /s/ Richard T. Schumacher

Richard T. Schumacher
President and Chief Executive Officer

Investor Presentation

Pressure BioSciences, Inc.
(OTCQB: PBIO)

*Discovery Starts
with Sample Preparation™*

Rodman and Renshaw
Global Investment Conference

September 10, 2014

Richard T. Schumacher
President, CEO, Board Member



Forward Looking Statements

This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company's products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company's filings with the Securities and Exchange Commission.



Company Overview (OTCQB: PBIO)

- 24 Patents: Pressure Cycling Technology (PCT) Platform
- 32M CS/CS Equivalents OS (Float ~12M) - approx
- Market Cap (fully diluted): \$8.3 Million
- Dvpt & Sale of PCT-based Products (Instruments & Consumables)
- 250 PCT Systems Installed, 150 Customers, 100 Publs - approx
- Early Revenue (grants/products): 2012 (\$1.2M), 2013 (\$1.5M)
- 1H 2014 Product Revenue (no grants): \$712K ...up 70%

**Support Research Labs WW with Novel & Enabling
PCT-based Sample Preparation Products**

Initial Focus: Biomarker Discovery & Forensics



Experienced Senior Management & Board

Management

- **Mr. Richard T. Schumacher, President & CEO**
Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen'l Mgr) - Harvard Medical School
- **Dr. Edmund Y. Ting, Senior Vice President of Engineering**
Avure Technologies (CSO); Flow Int'l (CSO); Grumman Aerospace; MIT (Ph.D.)
- **Dr. Alexander V. Lazarev, Vice President of R&D**
Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.)
- **Dr. Nathan P. Lawrence, Vice President of Marketing**
Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.)
- **Mr. Richard P. Thomley, Chief Financial Officer**
Kiva Systems; SynQor; Catamount Manufacturing; ChemDesign Corp

Board

- | | |
|-----------------------------------|--|
| • Jeffrey Peterson, MS | Chairman |
| • Kevin Pollack, Esq., MBA | Audit Committee Chairman |
| • Vito Mangiardi, MBA | Compensation Committee Chairman |
| • Mickey Urdea, Ph.D. | SAB Chairman |
| • Richard T. Schumacher | |



Value Proposition: PCT-based biological sample preparation

- Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers
- The Quality of Biomolecule Analysis Depends Significantly on the Quality of the Preparation of the Sample to be Analyzed
- Biological Sample Preparation is a Multi-Billion Market Comprised of an Estimated 500,000 Scientists in 80,000 Research Labs WW
- Current Sample Prep Methods are Highly Inadequate: Bottleneck
- Proven Platform: ~ 250 PCT Systems Installed (~150 Sites)
- Over 100 Publications Highlight the Clear Advantages of the PCT Platform Over Current Competitive Products
- Q1 2014: Released First-in-Kind Ultra-HP Instrument (100,000 psi)
- Q2 2014: Released our Novel, PCT-based Consumable for the Processing of Small Tissue Samples
- Q2 2014: Released our PCT High Throughput System (microwell strips)






Sample Preparation

Sample preparation is a term that refers to a wide range of activities that precede virtually all forms of scientific analysis. Sample preparation is often complex, time-consuming, and one of the most error-prone steps of scientific research. It is none-the-less a ubiquitous laboratory undertaking whose requirements drive a large and growing market, worldwide.

- **The Emmes Group (2008)**

Primary Sample Preparation for Biomolecular Analysis: Cell Lysis



PBI

Tools for Discovery

500,000 Scientists in 80,000 Biological Research Labs WW

Assortment of Analytical Instruments Used in the Discovery Process, e.g.,

- HPLC (est. of over 230,000 systems currently in use)
- Mass Spectrometers (est. of over 16,000 MS labs WW)
- DNA Sequencers, Real Time PCR
- Electrophoresis (1D, 2D, Western Blots, Southern Blots, etc.)
- Spectroscopy (NMR, EPR, CD, Raman, etc.)
- Immunoassay Analyzers (ELISA, RIA, microarrays, etc.)

What do all these analytical instruments have in common?

The quality of the results generated is directly related to the quality of the preparation of the sample to be analyzed

Sample Input Quality = Sample Result Quality



**Scientific research can be broken down to three key elements:
sample preparation, analysis, & data reduction/interpretation**

“Discovery Starts with Sample Preparation”

PBI

Biomarker/Forensics Market: Estimated Size

	<u>Estimated Market</u>
• Genomics (DNA/RNA)	\$7.1B in 2015 ^b
• Next Gen Sequencing (DNA)	\$2.7B in 2017 ^c
• Mass Spectrometry	\$2.7B in 2011 ^{a,d}
• Forensic Tools and Products (DNA)	\$17.7B in 2019 ^e
• Sample Prep for all OMICS:	\$8.4B in 2016 ^f
• 500,000 Scientists in 80,000 Biological Research Labs WW ^a	




^a EMMES Group ^b Decisive Bio-Insights ^c Markets & Markets

^d TechNavio ^e Transparency Market Rsh ^f bcc Research

PCT Sample Preparation System



Barocycler™
NEP2320




Barocycler™ NEP3229



PULSE Tube



MicroTubes



PCT-dependent Kits



Selected Marquee Customers (150)



HARVARD
MEDICAL SCHOOL



National Institutes
of Health

MONSANTO



BIOGEN

STANFORD
UNIVERSITY



AMGEN



PBI



MERCK

PCT Focus Area: Biomarker Discovery & Forensics

Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc.

Dr. Andreas Huhmer – **Thermo Fisher Scientific**

Dr. Michael Alterman – Tumor Vaccines and Biotechnology Branch, CBER, **FDA**

Dr. Alexander Ivanov – **Harvard School of Public Health**

Dr. Jennifer Van Eyk, **Johns Hopkins School of Medicine**

Dr. Wayne Hubbell, Distinguished Professor, Dept. of Chemistry & Biochemistry, **UCLA**

Dr. Hans Robert Kalbitzer, Professor, **University of Regensburg**

Dr. Ruedi Aebersold, Institute of Molecular Systems Biology, **ETH Zurich**, Switzerland

Forensics: Improved Processing of Rape Kits, Enhanced DNA Detection

Dr. Bruce Budowle, Health Science Center, **University of North Texas**


Dr. Bruce McCord, **Florida International University**

Dr. Dr. Henry C. Lee, **the Henry C. Lee Institute of Forensic Science**



The Barrier

Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities.



The Solution (4 years in the making)



June 2014 Release
ASMS Annual Meeting

- **Initial Application:**
 - High pressure digestion
- **Consumable:**
 - Proprietary 8-well strips
- **Number of Samples:**
 - 48 samples
- **User Control:**
 - Easy to use touch screen
 - LabView Software


PBI

The Future (is now)



PBI

Product Revenue Growth



Initial (Jan 2015) Commercialization: Barozyme HT48

The following is for discussion purposes only – not to be viewed as guidance

Enhanced Mass Spectrometry Sample Preparation

We Believe

- there are approx 16,000 MS labs worldwide (8,000 U.S.)
- most MS protein analyses require digestion of proteins prior to processing
- PCT offers enhanced quality of protein digestion

Barozyme HT48 Instrument could generate ~ \$25,000 instrument revenue on install

Barozyme HT48 Instrument could generate ~ \$6,000/year in BaroFlex consumable revenue

Then based on gaining a 20% market share over 5 years:

(3,200 customers x \$25K per Instrument)

\$16M in instrument sale plus \$19M in microwell strip consumable sales per year



Professor Wayne L. Hubbell

- Distinguished Professor of Biochemistry:
UCLA School of Medicine
- Assoc. Dir.: Jules Stein Eye Institute (UCLA)
- Member, National Academy of Sciences
- Fellow, American Academy of Arts and Sciences
- Member, UCLA Molecular Biology Institute & UCLA Brain Research Institute
- Gold Medal, International EPR Society



The Hubbell research lab is focused on the relationship between the molecular structure of a protein and the conformational changes that control its function

“In my opinion, high pressure will play a central role in the discovery process that lies ahead in the exciting field of protein science, and the PBI equipment will make major contributions to this field.”

PBI

Professor Jennifer Van Eyk

- Professor of Medicine, Cedars-Sinai Med. Ctr.
- Director, Basic Science Research, the Barbara Streisand Women's HC
- Director, Adv Clinical Biosystems Rsh. Institute
- Director, NHLBI Prot Innov Ctr, Heart Failure
- Formerly Professor of Medicine, Johns Hopkins School of Medicine
- Internationally Recognized Leader in the Field of Proteomics



The Van Eyk research lab is focused on studying the underlying molecular mechanisms of heart disease...

is seeking to discover novel changes in proteins that underpin the molecular mechanisms that drive disease...

and to develop new diagnostics and prognostic tests for clinical use.

Mr. David Weild IV

- Founder, Chairman, and CEO, IssuWorks
- CEO, Weild & Co Holdings (Inv Banking Firm)
- Former Vice-Chairman of NASDAQ
- Former Head of Global Equity Transactions, Prudential Securities
- Former President, PrudentialSecurities.com
- Former Head, Capital Markets Group of Grant Thornton LLP
- Known as the “Father of the JOBS Act”, according to Forbes Magazine



Pressure BioSciences Engages IssuWorks in Strategic Advisory Role

Pressure BioSciences has retained IssuWorks and their management team to review strategic and financing alternatives, including the possible spin-off of vertical market applications into new, stand alone businesses.

Key Investment Highlights

- **Pressure Cycling Technology (PCT): Powerful, Enabling, Patented**
- **Proven Technology: ~ 250 Installations in ~150 Marquee Laboratories**
- **Experienced Management Team and Board of Directors**
- **Large Market Opportunity (est. \$6 Billion; 80k Labs)**
- **Closed \$3.0M PIPE - *Final Tranche Expected to Close by 9/30/14***

Short Term Growth Drivers (2H 2014 into 2015)

- **On-going Discussions with Large Potential Strategic Partners**
- **“Razor/Razorblade” Business Model (Product Rev Up 70% in 1H 2014)**
- **New Products: Barozyme HT48 HUB880 u-Pestle**
- **Possible Spin-off of Vertical Market Applications**

